

THE WEEKLY BRIEF

By LYXOR CROSS ASSET RESEARCH

19 NOV 2020

MOST L/S EQUITY EMERGE UNSCATHED FROM FACTOR ROTATIONS



Philippe Ferreira
Senior Strategist

Jean-Baptiste Berthon
Senior Strategist

Bernadette Busquere Arnal
Hedge Fund Analyst

CrossAssetResearch@lyxor.com



A massive momentum reversal occurred earlier in the month, when Pfizer announced interim results of its Covid-19 vaccine. On November 9th, the U.S. Dow Jones Momentum Index fell by a record -14% in a single day. In this long/ short index, value stocks were on the short side and they experienced a massive rebound. Over recent days, such rotation out of momentum/ quality/ low beta into value/ size stocks has continued.

Several hedge fund strategies have momentum biases, in particular L/S Equity, and CTAs. Considering the fact that this rotation took place in a bullish environment, most hedge fund strategies ended the week in positive territory. Directional L/S Equity (+1.2%) benefitted from their market beta, but alpha contributed negatively for all but those strategies with an explicit value bias. One strategy benefitted particularly from the changing market landscape: Special Situations (+3%). In relative terms, their higher market beta and value bias was supportive.

CTAs and Market Neutral L/S ended the week in negative territory but losses, in the range of -1% to -1.5% according to the Lyxor Peer Groups, were overall contained. Dispersion has been high within the Market Neutral L/S space, with 20% of our sample down in excess of -3%, a significant loss for strategies which are traditionally low vol. Most managers have now neutralized their factor biases to edge against further rotations into value stocks.

Going forward, a sustainable rebound in value stocks looks unlikely, particularly in Europe. A significant part of their underperformance in recent years was also related to the low inflation/ low yield environment, which looks unlikely to change. Some value sectors such as financials might benefit from the gradual normalization in economic activity, which would occur in H2-2021, and could start to normalize dividend distribution next year. In parallel, momentum crashes are usually short lived. In this context, we maintain the UW stance on Market Neutral L/S and upgrade Special Situations to N.

A historic momentum reversal. A sustainable value rebound looks unlikely in Europe



Sources: Dow Jones, SG, Bloomberg, Macrobond, Lyxor AM

Hedge Fund Performance: Special Situations rides the value wave

	Last Week*	MTD	YTD	# of funds
MSCI World	2.7%	10.0%	8.2%	
Event-Driven: Special Situations	3.0%	5.2%	-1.5%	7
L/S Equity Directional	1.2%	3.7%	1.2%	52
Global Macro	1.6%	2.2%	-0.8%	51
Global Lyxor UCITS Peer Group	0.3%	1.7%	-1.5%	218
L/S Credit	0.4%	1.5%	2.0%	27
Event-Driven: Merger Arbitrage	0.6%	1.1%	-0.2%	21
Bloomberg Barclays Global Aggregate Bond Index	-0.2%	0.1%	4.8%	
Risk Premia	-0.8%	0.1%	-10.8%	13
CTAs	-1.7%	-0.5%	-6.0%	24
L/S Equity Market Neutral	-1.0%	-0.6%	-2.3%	23

*As of November 13th. Source: Bloomberg, Lyxor AM


Vaccine availability would be a game changer for the global economy next year. In anticipation of such normalization, markets experienced strong moves last week. Special Situation strategies, which have a value bias, benefitted the most from the news.

In turn, Market Neutral L/S, which have a momentum bias, suffered from the factor rotation.

The remaining strategies were relatively immune to such factor rotations but benefitted from the rally in risk assets. Global Macro strategies did well overall (+1.6% last week). Every sub-Macro strategy did well, with EM Macro outperforming slightly so far this month.

L/S Credit and Merger Arbitrage benefitted less from the market rally due to their moderate/ low market beta but both ended the week in positive territory as well.

Momentum is a risky risk factor which pays off over the long run




Momentum remains the best performing risk factor over the long run, compared to size, value, low beta, and quality. Yet, it is a risky risk factor with a maximum drawdown which reached 57% back in 2014. Meanwhile, the maximum drawdown of the value factor, at 52% was reached earlier in H2-2020.

Based on such considerations, there is room for value stocks to recover from their sharp losses registered in 2020. Yet, the upside remains capped, at least in the EMU, by low inflation prospects.

Momentum is also the most volatile risk factors, with an annualized volatility of 13.5% over the past ten years, vs. 10.4% for Value.

The Covid-19 vaccine caught Market Neutral L/S on the long momentum side



Based on our estimates, Market Neutral L/S strategies were significantly exposed to the momentum risk factor before the reversal, with a beta slightly above 12%. This suggests that at 10% fall in the momentum risk factor would imply a -1.2% loss in Market Neutral L/S strategies, all else being equal.

Since the momentum risk factor lost -13.3% last week, it would have suggested a -1.6% fall in Market Neutral L/S. Yet, their short exposure to the anti-beta risk factor, which lost -8.6% last week, helped offset losses on momentum exposures.

Our stance on the strategy remains UW. It is a defensive strategy, which is thus less attractive in a context where the next economic recovery, propelled by the vaccine availability, is likely to be around the corner. This suggests having some beta in portfolios would fuel performance, while factor rotations are likely to continue to pose hurdles for Market Neutral L/S.


METHODOLOGICAL APPENDIX

The information contained in this report on the performance of hedge funds is based on publicly available information. The universe of underlying funds is relatively stable but varies depending on the criteria of inclusion presented below. It is based on an unbiased selection from our hedge fund analyst team.

Performance is calculated on a weekly basis, as of end-Tuesday, using an arithmetic average (equally weighted average).

Regarding share classes used in these peer groups, we selected the primary share class as referenced in Bloomberg. Non-USD share classes are hedged in USD based on hedging costs available on Bloomberg.

Lyxor Hedge Fund Peer Groups: number of funds by strategy



- 220 strategies across the main categories in the industry
- USD 174 billion of assets under management

Criteria of inclusion

The criteria of inclusion are fourfold:

- We only include UCITS strategies;
- Assessment by Lyxor's Hedge Fund selection team based on funds' materials or manager interaction;
- We only include strategies with assets under management of at least USD 50 million; and
- We only include strategies with at least a one-year track record.

-

DISCLAIMER

The circumstances in which this publication has been produced are such that it is not appropriate to characterize it as independent investment research as referred to in MiFID and that it should be treated as a marketing communication even if it contains a research recommendation. This publication is also not subject to any prohibition on dealing ahead of the dissemination of investment research. However, Lyxor is required to have policies to manage the conflicts which may arise in the production of its research, including preventing dealing ahead of investment research.

This material has been prepared solely for informational purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell any security or financial instrument, or to participate in any investment strategy. This material does not purport to summarize or contain all of the provisions that would be set forth in any offering memorandum. Any purchase or sale of any securities may be made only pursuant to a final offering memorandum. No advisory relationship is created by the receipt of this material. This material should not be construed as legal, business or tax advice. A more robust discussion of the risks and tax considerations involving in investing in a fund is available from the more complete disclosures incorporated into the offering documentation for such fund.

This material has not been prepared in regard to specific investment objectives, financial situations, or the particular needs of any specific entity or person. Investors should make their own appraisal of the risks and should seek their own financial advice regarding the appropriateness of investing in any securities or financial instrument or participating in any investment strategy. Before you decide to invest in any account or fund, you should carefully read the relevant client agreements and offering documentation. No representation is made that your investment objectives will be achieved. This material is not intended for use by retail customers.

Any descriptions involving investment process, risk management, portfolio characteristics or statistical analysis are provided for illustrative purposes only, will not apply in all situations, and may be changed without notice. Past performance is not indicative of future results, and it is impossible to predict whether the value of any fund or index will rise or fall over time.

While the information in this material has been obtained from sources deemed reliable, neither Société Générale ("SG"), Lyxor Asset Management S.A.S. ("Lyxor AM") nor their affiliates guarantee its accuracy, timeliness or completeness. We are under no obligation to update or otherwise revise such information if and when it changes. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. SG, Lyxor AM and their affiliates assume no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from an investment in any security or financial instrument described herein or in any other security, or from the implementation of any investment strategy. Lyxor AM and its affiliates may from time to time deal in, profit from the trading of, hold, have positions in, or act as market-makers, advisers, brokers or otherwise in relation to the securities and financial instruments described herein. Service marks appearing herein are the exclusive property of SG and its affiliates, as the case may be.

Hedge funds may invest in futures and other derivative instruments. Futures trading and other derivatives may permit extremely high degrees of leverage and expose the funds to, among other things, volatility, market illiquidity, market risks, legal risks and operational risks. Hedge funds may be exposed to risks relating to non-domestic markets, including, without limitation, risks relating to currency exchange, tax, lack of liquidity, market manipulation, political instability and transaction costs. An investment in a hedge fund is subject to a total loss. This presentation contains the views of Lyxor AM analysts and/or strategies. The views espoused in this presentation may differ from opinions and recommendations produced by other departments of SG.

Note about Indices: Indices are not available for direct investment. A comparison to an index is not meant to imply that an investment in a fund is comparable to an investment in the funds or securities represented by such index. A fund is actively managed while an index is a passive index of securities. Indices are not investable themselves, and thus do not include the deduction of fees and other expenses associated with an investment in a fund. Not all the funds that comprise indices cited herein are suitable for U.S. Investors as a result of, among other things, the implementation of the Volcker Rule. Please see the offering documentation for these funds for more details.

Notice to U.S. Investors: Any potential investment in any securities or financial instruments, the categories of which are described herein, may not be suitable for all investors. Any prospective investment will require you to represent that you are an "accredited investor," as defined in Regulation D under the Securities Act of 1933, as amended, and a "qualified purchaser," as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended (the "40 Act"). The securities and financial instruments described herein may not be available in all jurisdictions.

Investments in or linked to hedge funds are highly speculative and may be adversely affected by the unregulated nature of hedge funds and the use of trading strategies and techniques that are typically prohibited for funds registered under the '40 Act. Also, hedge funds are typically less transparent in terms of information and pricing and have much higher fees than registered funds. Investors in hedge funds may not be afforded the same protections as investors in funds registered under the '40 Act including limitations on fees, controls over investment policies and reporting requirements.

Notice to Canadian Investors: Any potential investment in any securities or financial instruments, the categories of which are described herein, may not be suitable for all investors. Any prospective investment will require you to represent that you are a "permitted client," as defined in Canadian Regulation National Instrument 31-103, and an "accredited investor," as defined in National Instrument 45-106. The securities and financial instruments described herein may not be available in all jurisdictions of Canada.

For more information, U.S. and Canadian investors and recipients should contact Lyxor Asset Management Inc., 1251 Sixth Avenue, New York, NY 10020 or invest@lyxor.com.

Notice to U.K. Investors: This communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorised and regulated by the Financial Conduct Authority in the UK under Registration Number 435658.

Source: This document has been prepared by Lyxor Asset Management S.A.S., 17 cours Valmy, 92800 Puteaux. Lyxor AM is a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/UE) and AIFM (2011/61/EU) Directives. Lyxor AM is also registered with the U.S. Commodity Futures Trading Commission as a registered commodity pool operator and a commodity trading advisor.